Simple Blood Test Can Detect Alzheimer's Decades Before Symptoms Appear

A recent study shows that a simple blood test measuring key proteins associated with Alzheimer’s can detect the disease decades before clinical symptoms emerge. The findings offer new hope for managing dementia by identifying risks as early as middle age. Published in The Lancet, the research indicates that Alzheimer’s markers may be present in middle age and linked to measurable cognitive differences. Experts state that blood tests for early brain changes could be a valuable tool for medicine.

Alzheimer’s occurs when amyloid and tau proteins accumulate abnormally in the brain. In this study, researchers measured levels of two biomarkers—amyloid and p-tau217—in the blood of 1,350 non-demented individuals in the US, with an average age of 61. Analysis found high biomarker levels in 86 patients, associated with worse cognitive performance, faster verbal memory decline, and slower processing speed over a five-year testing period.

A separate Lancet-published study suggests a new brain scanning method to detect tau protein tangles. Researchers compared the commonly used radiotracer Flortaucipir with a new agent, MK6240. In a study of 682 patients in the US and Canada, MK6240 identified twice as many positive tau cases in early brain regions compared to the old method, allowing for more precise disease detection before significant brain damage occurs.

Dr. Jacqui Hanley, Chief Research Funding Officer at Alzheimer’s Research UK, welcomed the findings. She said accurate blood tests would improve diagnosis due to being less invasive, scalable, and more accessible than expensive PET scans or lumbar punctures.

The Blood Biomarker Challenge initiative is working to make blood tests for dementia diagnosis available in public health services like the UK’s NHS by 2029. However, experts stress the need for further research on larger and more diverse populations before routine clinical use. Alzheimer’s is the most common form of dementia, accounting for 60-80% of global cases. Early detection via blood tests could transform public health policy and give patients more time for preventive care. (Telegraph/I-2)